Establishing Pediatric CNS Pharmacodynamic Measures as Tools to Enable Psychiatric Indications in Adolescents
ID: 360576Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/360576
Timeline
    Description

    The National Institutes of Health (NIH) is offering a cooperative agreement opportunity titled "Establishing Pediatric CNS Pharmacodynamic Measures as Tools to Enable Psychiatric Indications in Adolescents." This initiative aims to advance research in determining optimal dosing strategies for new psychiatric medications in children and adolescents suffering from serious mental illnesses, focusing on the development of central nervous system (CNS) tools and models to assess medication effects on the brain. The opportunity is particularly relevant for researchers with expertise in pediatric psychiatry, neuroimaging, and clinical pharmacology, as it seeks to improve the safety and effectiveness of pediatric clinical trials through the establishment of pharmacodynamic measures. Interested applicants can reach out to Dr. Margaret C. Grabb at mgrabb@mail.nih.gov or by phone at 301-443-3563 for further information, with the estimated synopsis post date set for December 13, 2025, and the close date anticipated for February 13, 2026.

    Point(s) of Contact
    Margaret C. Grabb, Ph.D.
    (301) 443-3563
    mgrabb@mail.nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional)," aimed at advancing the discovery and development of innovative treatments for mental disorders, including substance use disorders and alcohol use disorder. This initiative encourages collaborative efforts between academia and industry to support multidisciplinary research projects that focus on early-stage human studies and the development of novel therapeutic candidates and neuromodulation tools. The program is designed to complement private sector efforts and emphasizes the importance of data sharing and innovative approaches to mental health treatment challenges. Interested applicants must adhere to specific eligibility criteria and application instructions, with a submission opening date of January 25, 2025, and a total project period not exceeding five years. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-353.html.
    Maternal and Pediatric Precision in Therapeutics (MPRINT) Knowledge and Research Coordination Center
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity for the establishment of the Maternal and Pediatric Precision in Therapeutics (MPRINT) Knowledge and Research Coordination Center through a cooperative agreement. This initiative aims to enhance drug development and regulatory science for maternal and pediatric therapeutics by creating a pharmacology knowledgebase, utilizing real-world clinical data, and fostering innovative clinical trials, while also training the future workforce in this critical area. The total estimated funding for this program is $3,625,000, with one award anticipated, and interested parties can reach out to Lesly-Anne Samedy-Bates at lesly-anne.samedy-bates@nih.gov or by phone at 301-219-7492 for further information. The estimated synopsis post date is November 21, 2025, with a closing date for applications expected by March 2, 2026, and project commencement anticipated on December 1, 2026.
    National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the National Cooperative Drug/Device Discovery/Development Groups (NCDDG) funding opportunity, aimed at advancing innovative therapies for mental disorders through cooperative agreements. This initiative encourages applications focused on the discovery, preclinical development, and proof of concept testing of new pharmacological agents and neuromodulatory devices, with a strong emphasis on partnerships between academia and industry. The program is designed to facilitate the transition of drug and device solutions from discovery to early human trials, addressing critical mental health challenges. Interested applicants must comply with NIH registration and submission requirements, with application deadlines beginning on January 25, 2025, and funding awards potentially lasting up to five years. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-352.html.
    Discovery of in vivo Chemical Probes for the Nervous System
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at supporting the discovery of in vivo chemical probes for the nervous system, specifically targeting novel brain mechanisms. This initiative, led by the National Institute on Aging (NIA) in collaboration with the National Eye Institute (NEI), the National Institute on Drug Abuse (NIDA), and the National Institute of Mental Health (NIMH), seeks applicants who possess validated starting compounds for chemical optimization and bioassays to explore new analog compounds. The focus will be on developing small molecules that can enhance understanding of biological processes relevant to brain diseases, with an emphasis on innovative biological targets. Interested applicants can reach out to Dr. Paul G. Grothaus at grothausp@mail.nih.gov or call 240-688-6634 for further information, with the estimated synopsis posting date set for February 26, 2026, and a projected award date of April 5, 2027.
    Addressing Methodological Challenges with Clinical Trials of Psychotomimetic Agents
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Addressing Methodological Challenges with Clinical Trials of Psychotomimetic Agents," aimed at soliciting research applications that tackle the methodological issues associated with clinical trials involving psychotomimetic agents (PMAs). The focus of this initiative is to enhance the understanding of the therapeutic effects of PMAs, such as psilocybin and MDMA, which have shown potential benefits for mental health disorders like depression and anxiety, thereby increasing confidence in clinical trial outcomes. The estimated total program funding is $5 million, with approximately five awards anticipated, and interested applicants are encouraged to engage with the FDA prior to submission to ensure compliance with regulatory requirements. For further inquiries, potential applicants can contact Jonathan Sabbagh, Ph.D., at jonathan.sabbagh@nih.gov or by phone at 301-793-3534. The synopsis is expected to be posted on September 3, 2025, with applications closing on November 3, 2025, and awards anticipated by July 1, 2026.
    Establishing a Center for the Advancement of Substance Use Disorder (SUD) Pharmacotherapeutics through Training and Preclinical Support
    National Institutes of Health
    The National Institutes of Health (NIH) is seeking to establish a Center for the Advancement of Substance Use Disorder (SUD) Pharmacotherapeutics through a Cooperative Agreement aimed at enhancing the development of new pharmacotherapeutics for SUD. The Center will focus on educating researchers in formal product development and providing technical and financial support for initial experiments, with an emphasis on creating a product development curriculum and fostering collaborations within the research community. This initiative is crucial for advancing drug addiction research and supporting the translation of innovative concepts into practical applications. The estimated total program funding is $3 million, with one award expected, and interested parties can contact Dr. Tam Nguyen at Tam.Nguyen@nih.gov or (301) 451-1203 for further information. The estimated synopsis post date is November 21, 2025, with applications expected to close on January 27, 2026, and the project anticipated to start on September 1, 2026.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research on neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) and related dementias (ADRD) through the R01 grant mechanism. This initiative aims to encourage studies that enhance understanding of the biobehavioral and neurobiological mechanisms associated with NPS, with the goal of identifying novel therapeutic targets for treatment and prevention. The research is critical for improving care and management strategies for patients and caregivers affected by these conditions, aligning with national efforts to combat Alzheimer's disease. Applications are accepted from a diverse range of eligible institutions, with key submission dates from January 5, 2025, to June 5, 2026. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-065.html.
    Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)" aimed at advancing research in drug safety and effectiveness for pregnant individuals, lactating persons, and children. This initiative seeks to support innovative projects that develop novel methodologies, enhance understanding of drug mechanisms, and promote precision medicine to address significant unmet medical needs in maternal and pediatric health. Eligible applicants include a wide range of institutions, such as historically black colleges and universities, tribal colleges, and various nonprofit organizations, with funding available up to $275,000 over a two-year period. Interested parties should note that applications are accepted until December 16, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)" aimed at advancing precision medicine for pregnant individuals, lactating individuals, and children. This initiative seeks to support translational and clinical research that develops novel therapeutic tools, enhances understanding of drug mechanisms, and improves medication safety and efficacy for these vulnerable populations. The program emphasizes interdisciplinary collaboration to address unmet therapeutic needs and promote better health outcomes in maternal and pediatric medicine. Applications will be accepted starting January 5, 2025, with a closing date of May 7, 2026. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-110.html.
    New Approaches for Measuring Brain Changes Across Longer Timespans (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "New Approaches for Measuring Brain Changes Across Longer Timespans" (Funding Opportunity Number PAR-24-160). This initiative aims to encourage multidisciplinary research that innovatively measures brain activity, connectivity, and other aspects of neurodevelopment across various age groups, with a focus on longitudinal studies that can include both human and animal subjects. The opportunity is significant for advancing methodologies in brain research, particularly in understanding cognitive health and diseases over the lifespan. Interested applicants must submit their proposals by May 5, 2024, and include a Plan for Enhancing Diverse Perspectives (PEDP), adhering to rigorous methodological standards. For further information, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-160.html.